Advanced search
1 file | 667.56 KB Add to list

The many faces of interleukin-17 in inflammatory skin diseases

Reinhart Speeckaert (UGent) , Jo Lambert (UGent) , Lynda Grine (UGent) , Mireille Van Gele (UGent) , Sofie De Schepper (UGent) and Nanja van Geel (UGent)
(2016) BRITISH JOURNAL OF DERMATOLOGY. 175(5). p.892-901
Author
Organization
Abstract
Interleukin (IL)-17 is an emerging target for inflammatory skin disorders. Given the remarkable success of its therapeutic inhibition in psoriasis, the pathogenic role of this cytokine is being explored in other immune-mediated diseases. Interestingly, IL-17 is linked to particular skin conditions where its activation coincides with disease flares. The leading hypothesis for its contribution to proinflammatory signalling cascades is driving inflammasome activation. However, IL-17 stimulation also releases a range of noninflammasome-related cytokines from human skin. Furthermore, a role in cytotoxic responses and an important interplay with the microbiome is hypothesized. While treatment failure would be surprising in neutrophilic dermatoses, the picture might be more complex in lymphocyte-mediated conditions. Nonetheless, increasing insights into the pathogenesis suggest that beneficial responses are also probable in the latter conditions. Study of this pathway in the skin reveals some intriguing aspects of the IL-17-related immunological network.
Keywords
T-HELPER 17, SEVERE ATOPIC-DERMATITIS, ORAL LICHEN-PLANUS, GROWTH-FACTOR-BETA, ALOPECIA-AREATA, TH17 CELLS, CYTOKINES INTERLEUKIN, PYODERMA-GANGRENOSUM, IL-17, EXPRESSION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 667.56 KB

Citation

Please use this url to cite or link to this publication:

MLA
Speeckaert, Reinhart, et al. “The Many Faces of Interleukin-17 in Inflammatory Skin Diseases.” BRITISH JOURNAL OF DERMATOLOGY, vol. 175, no. 5, 2016, pp. 892–901, doi:10.1111/bjd.14703.
APA
Speeckaert, R., Lambert, J., Grine, L., Van Gele, M., De Schepper, S., & van Geel, N. (2016). The many faces of interleukin-17 in inflammatory skin diseases. BRITISH JOURNAL OF DERMATOLOGY, 175(5), 892–901. https://doi.org/10.1111/bjd.14703
Chicago author-date
Speeckaert, Reinhart, Jo Lambert, Lynda Grine, Mireille Van Gele, Sofie De Schepper, and Nanja van Geel. 2016. “The Many Faces of Interleukin-17 in Inflammatory Skin Diseases.” BRITISH JOURNAL OF DERMATOLOGY 175 (5): 892–901. https://doi.org/10.1111/bjd.14703.
Chicago author-date (all authors)
Speeckaert, Reinhart, Jo Lambert, Lynda Grine, Mireille Van Gele, Sofie De Schepper, and Nanja van Geel. 2016. “The Many Faces of Interleukin-17 in Inflammatory Skin Diseases.” BRITISH JOURNAL OF DERMATOLOGY 175 (5): 892–901. doi:10.1111/bjd.14703.
Vancouver
1.
Speeckaert R, Lambert J, Grine L, Van Gele M, De Schepper S, van Geel N. The many faces of interleukin-17 in inflammatory skin diseases. BRITISH JOURNAL OF DERMATOLOGY. 2016;175(5):892–901.
IEEE
[1]
R. Speeckaert, J. Lambert, L. Grine, M. Van Gele, S. De Schepper, and N. van Geel, “The many faces of interleukin-17 in inflammatory skin diseases,” BRITISH JOURNAL OF DERMATOLOGY, vol. 175, no. 5, pp. 892–901, 2016.
@article{7224207,
  abstract     = {{Interleukin (IL)-17 is an emerging target for inflammatory skin disorders. Given the remarkable success of its therapeutic inhibition in psoriasis, the pathogenic role of this cytokine is being explored in other immune-mediated diseases. Interestingly, IL-17 is linked to particular skin conditions where its activation coincides with disease flares. The leading hypothesis for its contribution to proinflammatory signalling cascades is driving inflammasome activation. However, IL-17 stimulation also releases a range of noninflammasome-related cytokines from human skin. Furthermore, a role in cytotoxic responses and an important interplay with the microbiome is hypothesized. While treatment failure would be surprising in neutrophilic dermatoses, the picture might be more complex in lymphocyte-mediated conditions. Nonetheless, increasing insights into the pathogenesis suggest that beneficial responses are also probable in the latter conditions. Study of this pathway in the skin reveals some intriguing aspects of the IL-17-related immunological network.}},
  author       = {{Speeckaert, Reinhart and Lambert, Jo and Grine, Lynda and Van Gele, Mireille and De Schepper, Sofie and van Geel, Nanja}},
  issn         = {{0007-0963}},
  journal      = {{BRITISH JOURNAL OF DERMATOLOGY}},
  keywords     = {{T-HELPER 17,SEVERE ATOPIC-DERMATITIS,ORAL LICHEN-PLANUS,GROWTH-FACTOR-BETA,ALOPECIA-AREATA,TH17 CELLS,CYTOKINES INTERLEUKIN,PYODERMA-GANGRENOSUM,IL-17,EXPRESSION}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{892--901}},
  title        = {{The many faces of interleukin-17 in inflammatory skin diseases}},
  url          = {{http://doi.org/10.1111/bjd.14703}},
  volume       = {{175}},
  year         = {{2016}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: